Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H17F3N6O |
Molecular Weight | 306.2875 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)CCCCN1C=CC(NC(=N)NCC(F)(F)F)=N1
InChI
InChIKey=ALCSGJCIESECFD-UHFFFAOYSA-N
InChI=1S/C11H17F3N6O/c12-11(13,14)7-17-10(16)18-9-4-6-20(19-9)5-2-1-3-8(15)21/h4,6H,1-3,5,7H2,(H2,15,21)(H3,16,17,18,19)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2874823Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1716826 | https://www.ncbi.nlm.nih.gov/pubmed/2903545 | https://www.ncbi.nlm.nih.gov/pubmed/18157166
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2874823
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1716826 | https://www.ncbi.nlm.nih.gov/pubmed/2903545 | https://www.ncbi.nlm.nih.gov/pubmed/18157166
ICI-162846 (5-((3- (N'- (2,2,2-trifluoroethyl)-guanidino)pyrazol-1-yl) valeramide) is a new histamine H2-receptor antagonist developed by Imperial Chemical Industries for treatment of peptic diseases. ICI-162846 shows the high degree of specificity for histamine H2-receptors and sustained inhibition of acid secretion.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1941 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2903545 |
8.67 null [pKd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2874823 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2874823
Four ICI-162846 doses (0.5, 1.0, 2.5 and 5.0 mg) were given as a single tablet in randomized double-blind fashion
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18157166
Chinese hamster ovary (CHO) cells stably expressing a cyclic AMP response element-secreted placental alkaline phosphatase (CRE-SPAP) reporter gene were secondarily transfected with the human histamine H2 receptor. Cells were grown to confluence in 24-well plates. The media were removed and the cells pre-labelled for 3 h with 3H-adenine by incubation with 2 mCi/ml [3H]-adenine in serum-free media (0.5 ml per well). The 3H-adenine was removed and each well was washed by the addition and removal of 1ml serum-free media. Serum-free media (1 ml) containing 100 mM 3-isobutyl-1-methylxanthine (IBMX) with or without the final required concentration of antagonist were added to each well and the cells were incubated for 30 min. Agonist (in 10 ml serum-free media) was added to each well and the plates were incubated for 30 min. When the intrinsic activity of the antagonists was assessed, the ligands were incubated for 5 h in the presence of 100 mM IBMX to maximize the changes in 3H-cAMP accumulation. The reaction was terminated by the addition of 50 ml concentrated HCl per well. The plates were then frozen, thawed and 3H-cAMP was separated from other 3H-nucleotides by sequential Dowex and alumina column chromatography.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
134778
Created by
admin on Fri Dec 15 15:50:43 GMT 2023 , Edited by admin on Fri Dec 15 15:50:43 GMT 2023
|
PRIMARY | |||
|
SJ96DC9C66
Created by
admin on Fri Dec 15 15:50:43 GMT 2023 , Edited by admin on Fri Dec 15 15:50:43 GMT 2023
|
PRIMARY | |||
|
84545-30-2
Created by
admin on Fri Dec 15 15:50:43 GMT 2023 , Edited by admin on Fri Dec 15 15:50:43 GMT 2023
|
PRIMARY | |||
|
DTXSID5020734
Created by
admin on Fri Dec 15 15:50:43 GMT 2023 , Edited by admin on Fri Dec 15 15:50:43 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD